Dassault Systèmes Articulates Interconnected Life Science Vision

Dassault Systèmes 2021 Analyst Conference Event Brief

By: Sandra K. Rodriguez, Senior Industry Analyst and Daniel R. Matlis, President

Dassault Systèmes continued to articulate its interconnected Life-Science vision at the 2021 Analyst conference.

“In the experience economy, business science and innovation are all about relationships,” said Bernard Charlès, Vice Chairman, Chief Executive Officer at Dassault Systèmes. “The real phenomenon of the platform is about building an interconnected continuous interactive loop with your value chain from design to user experience,” he added.

“We are not talking about upstream and downstream applications anymore, it’s a continuous flow of imagine, create, produce, advocate, value and use,” said Charlès.

While Axendia does not believe in force ranking vendors because there is no BEST (see: Who is the Best Technology Vendor?), Dassault Systèmes executives were the first to articulate their avant-garde vision to support the Life-Science value network from end to end.  This vision is backed by an impressive offering portfolio aimed at providing an interconnected and continuous interactive platform that supports the Life-Science value network from end to end. 

By the Numbers

It has been two years since Dassault Systèmes announced the acquisition of MEDIDATA. Today, the company is providing Life-Science domain focus and specialization across the organization and creating growth opportunities through a broader offering and synergies across the 3DS portfolio.

“The question – and we have the answer, is how are technology and data platforms going to keep up with the speed of biological innovation that is part of a new age of precision and sophisticated pharmaceutical and medical device development.” – Glen de Vries, Co-CEO and Co-Founder, Medidata.

  • 8,000 customers are now leveraging the 3D Experience Platform including all top 20 BioPharma and MedTech companies, as well as all top 10 CROs.
  • 50% of drugs and medical devices are designed by 3DS solutions.
  • 23,000 clinical trials and 45 billion clinical data points are being managed by 3DS.

Companies like Abbot, BioNtech, Incyte, Janssen, Moderna, Novo Nordisk and Tiniko all leveraged their investments in the 3DS platform to achieved success in 2020.  For example, MEDIDATA played a key role in Moderna’s ability to speed up clinical trials by collecting customer data directly from their homes.  Additionally, the 3DEXPERIENCE Platform offered the following benefits:

  • Abbott reduced development costs by simulating the virtual twin of medical equipment
  • Novo Nordisk accelerated and reduced insulin syringe development costs with the use of the digital twin
  • BioNtech accelerated the development of new therapies due to standardized research processes
  • Tiniko accelerated and reduced development costs of materials for biomedical use through simulation and digital continuity
  • Incyte achieved continuity of processes from research to production for better efficiencies

Dassault Systèmes is also focusing on and seeking to establish a leadership position in three strategic sectors: manufacturing; healthcare and life-sciences; and infrastructure and cities.

“We provide Life-Science companies and professionals with a scientific and business platform to imagine sustainable innovations, capable of improving patient and physician experience in the age of precision medicine,” said Claire BIOT, Vice President Life Sciences and Healthcare Industry at Dassault Systèmes.  The 3DS platform supports the innovation cycle from discovery through commercialization. 

The New Expedited Product Development Timeline

In healthcare and life-sciences, MEDIDATA played a key role in reducing the time it takes to bring a vaccine to market from 18 years to 11 months.  “We reduced the start time for clinical trials from what is typically 8 – 12 weeks, to 2 – 4 weeks, and that allowed clinical trials to finish faster and vaccines to get to market faster,” said Tarek Sherif, Co-CEO and Founder of MEDIDATA. Also noteworthy are the 5 Billion records from 250 Million patients that are in MEDIDATA’s historical clinical trial environment.  As patients continue to the move to the center of the ecosystem, real-world evidence and data are increasingly being relied upon by regulators.

In Brief

Dassault Systèmes continues to deliver on its Interconnected Life-Science Vision using the 3DEXPERIENCE platform to support end to end digital transformation from R&D through manufacturing, commercialization and post-market.

The company is also leveraging the experiences and knowledge it has gained in its core industries, such as Aerospace & Defense and Transportation & Mobility, to support innovation in Life-Science and Healthcare.   Patient-centricity and outcome-driven experiences are the core of its business innovation platform. Life-Science companies of all sizes are seizing the opportunity to transform how medical products are discovered, developed, produced, commercialized, and used. 

We will continue to monitor and report how Dassault Systèmes executes on its commitment to making its vision a reality for its customers and ultimately, each patient. 

Contact Research@axendia.com to schedule an Analyst Inquiry on this topic.

The opinions and analysis expressed in this Briefing Note reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this document is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This document is not intended to endorse any company or product and should not be attributed as such.

Scroll to Top
Share via
Copy link